A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter Ellis
Juravinski Cancer Centre at Hamilton Health Sciences Centre, Hamilton, ON Canada
Study Chair - Sara K Taylor
BCCA-Cancer Centre for the Southern Interior, Kelowna, BC Canada
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cross Cancer Institute
Edmonton, Alberta, Canada
Recruiting - Bcca - Kelowna
Kelowna, British Columbia, Canada
Recruiting - Bcca - Vancouver
Vancouver, British Columbia, Canada
Recruiting - Regional Health Authority B, Zone 2
Saint John, New Brunswick, Canada
Recruiting - Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Recruiting - Waterloo Regional Health Network (wrhn)
Kitchener, Ontario, Canada
Recruiting - Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Recruiting - University Health Network
Toronto, Ontario, Canada
Recruiting - Windsor Regional Cancer Centre
Windsor, Ontario, Canada
Recruiting - Chum-Centre Hospitalier de L'Universite de Montreal
Montreal, Quebec, Canada
Recruiting - Chu de Quebec-Hopital L'Enfant-Jesus (hej)
Québec, Quebec, Canada
Recruiting - Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Mar 2020
- Primary completion
- 30 Apr 2030
- Completion
- 30 Apr 2031
- Last update posted
- 17 Jun 2026
- Registered enrollment
- 60
- Registry id
- NCT03847649
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.